Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker

Clinical Pharmacology and Therapeutics

Volumn 72, Issue 2, 2002, Pages 192-199

  Kim, Myong Jin ^a,b,c   Bertino Jr , Joseph S ^a,b,c   Gaedigk, Andrea ^a,b,c   Zhang, Yanhua ^a,b,c   Sellers, Edward M ^a,b,c   Nafziger, Anne N ^a,b,c  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5' HYDROXYOMEPRAZOLE; BIOLOGICAL MARKER; CYTOCHROME P450 2C19; DIAZEPAM; DRUG METABOLITE; MEPHENYTOIN; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PROGUANIL; PROPRANOLOL; SEX HORMONE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE DOSAGE; GENOTYPE; HORMONE BLOOD LEVEL; HUMAN; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SEX;

ADULT; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLICULAR PHASE; GENOTYPE; HUMANS; LUTEAL PHASE; MALE; MENSTRUAL CYCLE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE; REFERENCE VALUES; SEX FACTORS;

EID: 0036693059     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2002.126174     Document Type: Article

References (35)

1. Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man
2. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators
3. Importance of genetic factors in the regulation of diazepam metabolism: Relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype
4. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities
5. The activation of the biguanide anti-malarial proguanil cosegregates with the mephenytoin oxidation polymorphism: A panel study
6. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype
7. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype
8. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin
9. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population
10. Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: Possible effect of age, liver disease, and length of therapy
11. Assays of omeprazole metabolism as a substrate probe for human CYP isoforms
12. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
13. Update on oral contraceptive pills
14. Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers
15. No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects
16. CYP2D6 and CYP2C19 activity in a large population of Dutch health volunteers: Indications for oral contraceptive-related gender differences
17. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe
18. Evidence for the effect of gender on activity of (S)-mephenytoin 4′hydroxylase (CYP2C19) in a Chinese population
19. The mephenytoin (cytochrome P450 2C19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos
20. S-mephenytoin hydroxylation phenotypes in a Jordanian population
21. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population
22. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography
23. Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism
24. m2 in exon 4, in Japanese subjects
25. Effect of age and sex on human drug metabolism
26. Gender effects in pharmacokinetics and pharmacodynamics
27. Regulation of the human menstrual cycle
28. Propranolol pharmacokinetics during the menstrual cycle
29. Phenytoin metabolism by human cytochrome P450: Involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation
30. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisopropylation is mediated mainly by CYP1A2
31. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population
32. S-mephenytoin 4-hydroxylation in older Americans
33. High-dose omeprazole: Use of a multiple-dose study design to assess bioequivalence and accuracy of CYP2C19 phenotyping
34. Genetic polymorphism of S-mephenytoin 4′-hydroxylation in African-Americans
35. Mephenytoin as a probe for CYP2C19 phenotyping: Effect of sample storage, intra-individual reproducibility and occurrence of adverse events